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Abstract The importance of a properly functioning and
well-balanced immune system for maintaining health has
become strikingly evident over the past decades. Roughly
since World War II, there has been an apparent decrease
in the prevalence of “traditional” infectious diseases, with
a concomitant increase in immune-related disorders, such
as allergies. Causally, a relationship with changes in life-
style-related factors such as the increasing use of
hygienic practices seems likely. Diet and nutrition can
affect the functioning of various immune parameters.
This concept can be utilised in attempts to prevent or
mitigate allergic reactions via the development of targeted
food products or ingredients. This review describes recent
findings with respect to food products and ingredients
that show potential in this respect, with special emphasis
on pro- and prebiotics, β-glucans and fungal immuno-
modulatory proteins. What all of these approaches have
in common is that they appear to strengthen Th1-
mediated immunity, thus possibly restoring defective
immune maturation due to overly hygienic living con-
ditions: a little bit of dirt does not seem bad!
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Introduction
The importance of a properly functioning and well-
balanced immune system for maintaining health has
become strikingly evident over the past few decades.
There has been, roughly since World War II, an apparent
decrease in the prevalence of “traditional” infectious
diseases, such as tuberculosis, mumps, or measles, with
a concomitant increase in immune-related disorders, such
as multiple sclerosis, irritable bowel disease, type 1
diabetes and various allergic diseases. In addition, a
“gradient” in disease incidence can be observed, decreas-
ing in the north–south direction in the Northern Hemi-
sphere, and vice versa in the Southern Hemisphere [1].
Such observations suggest a relationship with nongenetic
factors, such as (changes in) health care and medical
practice, (changes in) living environment and lifestyle,
level of welfare, dietary habits, and the like. In particular, it
has been hypothesised that the strong increases in rates of
asthma and allergic disease are related to the increased use
of hygienic practices and the subsequently reduced expo-
sure to microbes, which supposedly results in an “under-
educated” immune system [2]. This includes food hygienic
practice, the tremendous virtues of which cannot be
disputed, but which may have contributed to impaired or
delayed immune maturation. Also, the rise in food products
that are composed of highly refined ingredients has led to
the decreased consumption of micronutrients, which may
be relevant to immune maturation [3]. Interestingly, the
incidence of tuberculosis was reported to be inversely
related to the incidence of asthma and rhinoconjunctivitis,
confirming the importance of a vigilant Th1 compartment
in disease aetiology, as mycobacteria elicit particularly
strong Th1 responses [4]. Not just in atopic disorders, but in
many other chronic diseases—for instance cardiovascular
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diseases, neoplastic malformations, and metabolic syn-
drome—chronic inflammatory processes are involved,
possibly causally, in the development of subsequent related
health problems, also suggesting an important role for
immune interventions [5–9]. The prophylactic and thera-
peutic relevance of immune modulation is confirmed by the
possibility of developing antitumor strategies via vaccina-
tion, such as as has been described for Mycobacterium-
based vaccines and lung tumours, an effect supposedly
based on selective enhancement of Th1-mediated immunity
[10], and the claimed prophylactic effect of the
Th1-stimulating mushroom-derived β-glucan lentinan on
malaria [11], which all adds to the evidence that a better
comprehension of and capacity to maintain immune
homeostasis is of extreme importance to both individual
and public health.
Immune modulation, for example via dietary strategies,
may hold promise as well for maintaining immune
homeostasis in the healthy population. Immunity, described
as the activities of its various compartments, strongly varies
throughout life. For instance, there is a decline in the
functional capacity to elicit generalised and specific
immune responses with increasing age, and regulatory cells
show a decrease in production and response to regulatory
signals. Overall, these developments result in the impair-
ment with age of innate and adaptive immune responses,
increased self-antigen reactivity, increased incidence of
infection, and increased vulnerability to the development
of neoplastic malformations. Overall, the implications of
such immune phenomena associated with senescence are
that susceptibility to specific health conditions may vary
with age, with immune impairment eventually leading to
increased risk of mortality [12–16]. Although still in its
infancy, the use of dietary factors, notably vitamin E and
ω-3-PUFAs, as tools to circumvent this age-related decline
in immune function is a focus of research [17].
Dietary components and immunity
The question “which food components impact on the
functioning of specific immune compartments?” could
perhaps better be phrased as “which food components do
not have an impact on immune function?”. Protein energy
malnutrition (PEM), for instance, affects all aspects of
immune function, with these effects being even more
pronounced in the elderly. The functioning of T-cell and
B-cell subsets and functions and of innate immunity are
strongly related to protein nutritional status. Immune
responses can be restored by relieving this protein shortage,
but at a slower speed in patients that suffer from
inflammatory processes. The imbalance between normal
macrophage functions and decreased T-cell function is
partly responsible for chronic inflammatory processes in
vulnerable patients. Acute phase responses are, for these
reasons, more detrimental to nutritional status and nutrient
reserves in elderly patients than in adults [18, 19]. The
dietary protein:carbohydrate ratio appears to be important
in maintaining immune responsiveness; maintaining low
protein and high carbohydrate levels for prolonged intervals
seems to be beneficial, as evidenced in a rat model [20].
The concept of dietary components being of paramount
importance to immune function is also tangible in the
formulation of so-called immunonutrition, specific nutri-
tional preparations for clinical use in critically ill patients
with jeopardised immune function. Such preparations
contain specific amino acids such as arginine and gluta-
mine, nucleotides, and specific polyunsaturated fatty acids,
notably ω-3 PUFAs [21, 22].
Immune function is the target for the development of
functional foods. In particular, vitamins, such as A, C, D and
E, and minerals as Zn and Se are focal points for this, next to
PUFAs such as docosahexaenoic acid (22:6n-3; DHA) and
eicosapentaenoic acid (20:5n-3; EPA). A detailed essay on
the immunomodulatory properties of each of these nutrients
is beyond the scope of this paper, so the reader is referred to
a number of recent reviews and research papers that deal
with these matters [21–26], and references therein. For a
number of other nutrients and products, research is still in a
less advanced stage—at the stage of in vitro or animal
models at best—and some research issues in this field will be
dealt with below.
Therefore, there seems to be a role for food and nutrition
in supporting and maintaining immune homeostasis for
various groups of individuals. It should be realised,
however, that research into the possible role of functional
foods in mitigating (human) immune function is still in its
infancy, and that controversy around health claims will
remain the rule rather than the exception so long as there is
no improvement in (for example) the identification of
suitable biomarkers, and in our comprehension of individ-
ual responses (genetics and imprinting) and the underlying
physiological and biochemical mechanisms associated with
nutrients.
The conclusion that modulating immune response may
well serve as the basis for the development of functional
foods appears at hand. Before such approach can achieve its
full potential, however, it is essential to realise that
functional foods should be regarded as food products with
specific health benefits (above those of average consump-
tion levels) for targeted groups of consumers. Therefore, the
specific needs of individuals or groups of individuals must
be matched with the immunomodulatory properties of
specific products. Products that may be of benefit to, for
example, allergic consumers do not necessarily have a
beneficial effect on other consumers with different require-
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ments for immune mitigation; requirements for neonates
likely differ from those of the elderly, and so on: one size
does not fit all!
Objective and rationale
The objectives of the research area are to develop
immunity-related markers for health effects of food, and
to develop dietary or food products to support vital and
balanced immune function throughout life.
Immunological read-outs are used to determine possible
health effects because:
& A variety of chronic health threats that have an
enormous economic impact and also impact on quality
of life are directly related to immune function, such as
autoimmune diseases, allergies and asthma, and im-
mune deficiencies.
& The immune system plays a role in the pathology of
chronic and age-related anomalies; in some cases a
causal one (or perhaps only partially so).
& There is increasing evidence (from randomised double-
blind intervention studies and clinical trials too) of the
capacity of food components to modulate the response
of the immune system, both positively (immune-
potentiating) and negatively (e.g. food allergy).
The analysis of the capacity and activity of the immune
system offers advantages that may facilitate the translation
from an experimental setting to possible application and
implementation, because of the pivotal role of the immune
system that has been acknowledged in health analysis and
clinical practice:
& For many immune functions, diagnostically validated in
vitro or in vivo test systems are available
& For many immune functions, animal models and cell
lines for in vitro analysis are available
& The role of the immune system in clinical practice and
the pathology of many chronic anomalies is relatively
well documented.
& There is an increased interest in linking individual
immune reactivity to lifestyle- and age-associated
factors, where food and nutrition show the best
documented effects.
The current lack of mechanistic underpinning of the
health effects of food intake results in sometimes contra-
dictory claims and statements, confusion, and a loss of trust
and confidence amongst consumers. Addressing this lacuna
will contribute to a solid basis for health claims, and
consequently to the concept of “health promotion via
nutrition”. Immune modulation offers unique perspectives
for meeting such requirements.
Types of products with immunomodulatory
claims that are currently on the market
Despite the relative infancy of the state of scientific
understanding of interactions between immunity, food and
diet at present, there are already a number of products on
the market for either clinical, food or feed-related
applications. Since this paper is not an “advertorial”, no
specific products will be mentioned, but some product
groups with more or less specific applications will be
indicated:
& “Immunonutrition”. Immunonutrition-type products are
typically meant for clinical use for critically ill or
surgical patients, to fortify hampered immune function.
Application routes can be either parenteral or enteral;
the optimal route may depend on patient and disease
characteristics. Typical components included in such
products are specific amino acids (notably glutamine
and arginine), nucleotides, ω-3 PUFAs, minerals such
as Zn and Se, and various compounds with antioxida-
tive properties [21–31]. Since immunonutrition is used
in relatively well-described clinical cases, with relative-
ly well-defined end-points, there is a rather well-
elaborated scientific basis for its application.
& Pro- and prebiotics. Probiotics are, by definition,
“nonpathogenic microorganisms that when given in
adequate numbers exert beneficial effects on the host”,
whereas prebiotics are a category of functional food
defined as “nondigestible food ingredients that benefi-
cially affect the host by selectively stimulating the
growth and/or activity of one or a limited number of
bacteria in the colon, and thus improve host health”
[32]. A number of beneficial health effects have been
claimed for the pro-pre-biotic product category, includ-
ing effectiveness against antibiotic-associated or travel-
lers diarrhoea, improved stools, as well as an array of
immunity-related health claims, also in relation to
allergic disease.
Fructose oligosaccharide and galactose oligosaccha-
ride fortified infant formulas are currently on the
market; these are intended to support the developing
immune systems of neonates (see below for more detail,
and [33] for an extensive review of various health-related
claims).
& Hypoallergenic infant formulas. A product category that
has the immunomodulatory property that it does not
activate a potentially anomalously reacting immune
response. Hydrolysed preparations of milk proteins are
in the market, and these are aimed in particular at
circumventing clinical reactions in individuals allergic
to cow’s milk. The degree of protection is usually quite
good, and dependent on the degree of hydrolysis [34].
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Again, this concerns a category of relatively well-
defined patients with a relatively well-understood
clinical history.
& β-Glucan-containing preparations for feed applica-
tions. In an attempt to limit the use of antibiotics in
animal husbandry, spent brewer’s yeast is added to feed
in order to increase natural resistance. This effect is
attributed to β-glucans, which are present in yeast cell
walls, and are supposed to interfere with and enhance
immunity (see e.g. [35]). Preparations that claim an
enhanced accessibility of β-glucans to the immune
system are even marketed.
& Various supplements. A plethora of various kinds of
food supplements are available on the market, which are
too large in number and too variable in composition (if
they can be defined at all) to be discussed comprehen-
sively here. However, they often have a common
denominator, in the sense that there is only very meagre
underpinning of claims, and indications of who should
or could take such preparations and when are scarce.
Research into immunomodulation
by food, with a focus on allergy
Probiotics
Probiotic bacteria are nonpathogenic microorganisms that
are thought to exert positive health effects on the host. In by
far the majority of cases, Lactobacillus or Bifidobacterium
spp. are the microorganisms endowed with the supposed
beneficial effects; nevertheless, it should be noted that the
distinction between “good” and “bad” organisms is a rather
arbitrary one, and is strongly dependent on where in the
digestive tract, and to whom, they are applied [36]. Some
years ago, relationships between the composition of
intestinal microbiota and the occurrence and incidence of
allergic diseases were noted [37–39]. In particular, a
comparison between Estonian and Swedish school children
demonstrated that allergic children were less often colon-
ised with Lactobacilli and more often with aerobic coli-
forms and Staphylococcus aureus [37, 38], or lower
Bifidobacterium counts and higher Clostridium colonisation
numbers were found [39]. This was supposed to be relevant
to the proper maturation of intestinal immunity, and in
particular to impact on the balance between Th1 and Th2
cells [38, 39], thus suggesting options for nutritional and
dietary intervention, via probiotics, for this type of
condition.
Indeed, when Lactobacilli (LGG) was given to 159
pregnant women (at risk of allergy) for two weeks and to
their babies for six months, 50% fewer infants in the LGG
group than in the placebo group demonstrated atopic
eczema at two years of age [40]. Similarly, LGG and
Bifidobacterium lactis Bb12 were shown to decrease the
severity of atopic eczema [41]. In a similar study, serum
tolerance-related cytokine IL-10 was elevated significantly
in the LGG group [42]. Furthermore, administering L. casei
Shirota was found to significantly suppress the production
of IL-5, IL-6 and IFN-γ compared to placebo in PBMCs of
(adult) sufferers from seasonal allergic rhinitis [43].
However, results sometimes were reproducible elsewhere
[44], or they were not, e.g. in the development of atopic
dermatitis [45]. Also, in a group of teenagers and young
adults, the application of Lactobacillus rhamnosis did not
alleviate birch-pollen allergy symptoms [46]. Furthermore,
dietary LGG supplementation a few weeks before delivery
did not appear to have an effect on the proliferative
response of PBMCs from atopic or control neonates, thus
suggesting that there was no impact on sensitisation
potential [47].
In conclusion, results in allergy prevention are still
variable and heavily debated. In vitro observations suggest
that a possible mechanism for positive effects on allergy-
related immunity is the restoration of imbalances between
various T-cell subsets, perhaps indirectly via TLR signal-
ling in innate immune cells. In vivo results may be strongly
strain dependent, as a variety of immune effects, e.g. IL-10
inducing (tolerance enhancing?) or Th1 skewing, may be
observed during the in vitro screening of probiotic strain
collections [Vissers et al., publications in preparation].
However, effects on gut permeability or intestinal allergen
processing cannot be excluded. Also, responses may
depend on individual patient characteristics as well, such
as whether allergies have already fully developed or not.
Recently, interactions between (inducible) Lactobacillus S-
layer protein and gut DCs were described that may
contribute to the mechanism of action [48], primarily in
relation to innate immunity.
In addition to allergic disease, probiotics are being
investigated in for example celiac disease, gastroenteritis,
IBD, colon and colorectal cancer, and antibiotic-associated
diarrhoea [33].
However, above all, the conclusion is that stringent
requirements for experimental design are imperative to
avoid contradictory data, and to further this promising area
of research.
β-Glucans
β-(1→3)-(1→6)-Glucans are rather ubiquitous polymers of
glucose with a β-(1→3) backbone and β-(1→6) crosslinks,
with typical Mr values in the range of several hundreds of
kDa, indicating Dp values of several thousands of glucose
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units, and are the subject of research in relation to their
anticipated effects on immunity, in particular via binding to
cells from the innate immune compartment such as macro-
phages and to NK cells [47, 48]. This type of glucan can be
found in bacteria, yeasts, fungi [51], seaweed [52] and
cereals (the latter mainly containing (1→4) crosslinks [53]).
Kimura et al. described a mitigating effect of (orally
administered) β-glucans on food allergic reactions in
mouse models. Adding 0.5–1.0% of a β-glucan from
Aureobasidium pullulans strain A1 to the diet of
ovalbumin-allergic Balb/C mice considerably reduced ova-
specific IgE and stimulated IL-4, IFN- and IL-12 produc-
tion in ConA-stimulated splenocytes from the mice [54].
Oral application of finely dispersed shiitake β-glucan
(lentinan) in human patients allergic to cedar pollen
significantly alleviated the symptoms of Japanese cedar
pollen-induced rhinitis, sneezing, nasal congestion, and
conjunctivitis, and its oral uptake before symptom onset
exhibited preventive effects. Allergic symptoms were
relieved not only for seasonal allergies to cedar pollen but
also for perennial allergies. Oral ingestion of β-(1→3)-
glucan in individuals with allergic tropism could reduce the
spontaneous increase in both allergen-specific and total IgE
titers, and the clinical responses to treatment were well
correlated with the capacity of monocytes to bind to β-
(1→3)-glucan [55]. Both the route of application (nasal
application of β-glucans, resulting in the glucans acting as
an allergen [54]) and the degree of dispersion appeared
important, as nondispersed lentinan did not give the desired
effects [55].
Similar (peanut) allergy relieving effects were observed
in C3H/HeJ mice, for an orally applied complex herbal
preparation in which β-glucans (from the fungus Gano-
derma lucidum) were undoubtedly present [56]. Also, again
orally applied, G. lucidum preparations were effective in a
mouse model for house dust mite allergy [57].
β-Glucans appear to exert their immunomodulatory
effects via the activation of innate pathways, e.g. in
macrophages ([49, 50] Fig. 1). β-Glucans were found to
stimulate the production of TNF-α, IFN-γ and IL-12 when
injected into ICR mice [58], as was also found in models of
human peripheral blood mononuclear cells in which various
fungal extracts were screened [59], although there is also a
report that shows a somewhat different picture for Aur-
eobasidium pullulans; in that report, IL-8 production in
PBMCs and in a monocyte cell line was detected [60].
Activation of T-cells in PBMC cultures is probably an
indirect effect of the stimulation of innate cells, and
reaction cascades may depend on typical characteristics of
β-glucans such as Mr (the Aureobasidium glucan being
relatively small, ca. 100 kDa, and highly branched (50–
80%) [54]), which can perhaps account for (some of) the
differences in observations. A number of receptors for β-
glucans (dectin-1, complement receptor 3, TLR2 and
TLR6, scavenger receptors and lactosylceramide) have
been described. Dectin-1 is particularly commonly
expressed on immune cells, such as dendritic cells, macro-
phages, monocytes, neutrophils, eosinophils, some T-cells
and in humans on B-cells too. The possible expression of
dectin-1 on intestinal cells is under debate [49]. The
interaction of dectin-1 and TLR2 upon β-glucan binding
leads to synergistic effects on the production of cytokines
such as TNF-α and IL12, a process in which NF-kB [59]
and spleen tyrosine kinase are claimed to be involved [62].
Receptor binding studies in which the Ig-labelled
polysaccharide-binding domains of dectin-1 were used to
detect glucan binding have demonstrated that dectin-1
preferentially binds to the β-(1→3) part of the glucan,
and that the minimal length required to allow binding to
dectin-1 is 10–11 glucose residues [63]. It should be
realised that these observations were derived from an
abstracted experimental model, leaving the physiological
significance of the β-(1→6)-branches as yet unanswered.
As the binding of β-glucans to dectin and TLR-2 shows
synergistic effects, perhaps there is a role for the β-(1→6)-
Fig. 1 Conceptual model for the interaction between β-glucans and
innate immune receptors as expressed on macrophages. Interaction
between dectin-1 and the TLRs leads to synergistic responses
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branched structure in this effect [61]. Single-chain β-
glucans appear to induce stronger responses (NF-kB, iNO
production, TNF-α) in (murine) macrophages than oligo-
meric chains do [50]. Increasing the solubility of β-glucans,
for instance by preparing sulfated, carboxymethylated,
methylated, hydroxyethylated or hydroxypropylated deriv-
atives, increased their activity against Sarcoma-180 tumour
cells [64], the effectiveness of which in relation to allergy
mitigation can only be speculated on.
Taken altogether, there appear to be clear indications,
from both animal models and from a human study, that
orally applied β-glucans or glucan-containing preparations
can be of help for relieving various allergy-related
symptoms. Applications of Th1 stimulation are anticipated
not only in allergy mitigation but also in the stimulation of
cell-mediated immunity and increased infection resistance.
It appears as if these compounds activate (indirectly via
primary innate activation) Th1-mediated immunity, primar-
ily via activation through TLR/CLR (dectin) signalling.
More details on their mode of action, such as for
instance how and where interactions between ß-glucans
and immune cells take place (via intestinal microfold-(M-)
cells? Via, into the intestinal lumen protruding, dendritic
cells? Transport via tight junctions (para-cellular transport),
as well as structure-function studies and research on
application and delivery methods, for instance incorpora-
tion into food products or supplements, will be essential to
further develop this promising research direction.
Fungal immunomodulatory proteins (FIPs)
FIPs are 15 kDa proteins of (as far as we are aware so
far) fungal origin. A number of FIPs have been described
in some detail, including those from Flammulina velu-
tipes (golden needle mushroom; FIP-fve), Volvariella
volvacea ((paddy) straw mushroom; FIP-vvo), Ganoderma
lucidum and G. tsugae (Japanese lacquer mushroom; LZ-
8 and FIP-gts, resp.), which are composed of 114 (FIP-fve),
110 (LZ-8 and FIP-Gts) and 112 (FIP-vvo) amino acids,
respectively, and share high sequence homology ([65] and
Fig. 2). FIP-fve was crystallised and its X-ray structure
determined [65, 66]; it was found to be a homodimer where
each subunit comprises a pair of N-terminal secondary
structural elements, an α-helix followed by a β-strand
linked to a domain consisting almost exclusively of β-
sheets adopting an Ig-like fold, with α-helix, β-strand and
loop fractions of respectively 11.3, 42.6 and 46.1% [66].
The α-helices HA and HB are amphipathic and the side
chains of the amino acids on the hydrophobic face of one
helix pack well against those of the other α-helix, enabling
them to bind via hydrophobic interactions. Lin et al. [68]
predicted that the N-terminal residues 1–13 of FIP-Gts
formed an α-helix, and they found that recombinant
mutants of FIP-Gts in which residues 1–13 (the N-
terminal α-helix) were deleted were incapable of dimer-
isation. Triple mutants in which Leu5, Phe7 and Leu9
were deleted lost their amphipathic character, the ability to
form dimers with themselves and with the wild-type FIP-
Gts protein, suggesting that this property was important
for immunomodulatory activity [67, 68]. FIPs show lectin-
like properties, as they are able to agglutinate erythro-
cytes, and it was suggested that they should be classified
as such [67].
The biological relevance of FIPs for allergy mitigation
lies in the observation that they were able to inhibit food-
allergic and respiratory-allergic reactions in mouse models
when applied orally or nasally. When fed (at 200 mcg/
mouse, i.e. ca. 4 mg kg−1, every other day) to ovalbumin-
allergic Balb/c-mice, allergy symptoms (symptom score,
histamine release, intestinal damage) were strongly sup-
pressed, and the Th2-dominant phenotype shifted towards a
strongly elevated Th1 response (measured in splenocytes)
upon FIP feeding, showing its potential in allergy prophy-
laxis [69]. Liu et al. found that FIP-fve could be applied in
local nasal immune therapy to suppress allergic responses
to house dust mite allergy in Balb/c mice [70], and a shift in
cytokine profile towards a stronger Th1-response was also
noted in this study.
   
    
Fig. 2 Sequence alignment of FIPs from various sources, demonstrating homology; see text
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Not many details on the putative mode of action of FIPs
have been published, other than that FIP-fve appeared to
stimulate IFN-γ production in human PBMCs via p38-
MAPK activation [71]. Our own observations ([72], and
unpublished results) indicate that natural FIPs or cloned
FIPs from Flammulina or Ganoderma have a limited effect
on NO production in RAW 264.7 cells (a murine monocyte
cell line), and a Th1-skewing effect in human PBMC
cultures from healthy volunteers. This was partly corrobo-
rated by observations for a immunomodulatory protein
from Auricularia (Jew’s ear) mushroom, a protein that
perhaps (although this is not yet confirmed) should also be
considered a FIP, of Th1 skewing but not NO production in
RAW 264.7 cells [73].
One interesting aspect, considering their potential appli-
cation as food-derived immunomodulatory compounds, is
the apparent resistance of the biological activity of these
FIPs to common food processing conditions, such as
freezing, thawing, dehydration, and acid/alkali conditions
[74, 75].
Questions as to their digestion stability, and on the
signalling mechanisms (again: absorption via tight junc-
tions (para-cellular transport), DCs, M-cells, signalling via
GALT?) remain to be answered.
Perspectives
Based on the above, the option of immunomodulation via
diet appears to be a realistic option, with advantages for
specific immune-related conditions such as allergies at the
very least, although perhaps also in other application areas
too, such as in maintaining immune homeostasis and
vigilance. Considering the pivotal role of immune homeo-
stasis in general health, and the very relevant and
significant societal and economic perspectives, this research
avenue seems to be a very worthwhile one, to say the least.
It appears as if different food components can exhibit
effects on specific immune compartments, thus offering the
potential for use in a variety of applications, depending on
the characteristics of the deviating chronic processes and
the characteristics of the consumers or patients. Foods can
thus play a significant role in fortifying and balancing
immune responses.
As it becomes more and more clear that the aetiology
and course of a given “disease” varies from person to
person, it also appears increasingly obvious that treatments
(or, if possible and appropriate, supportive dietary meas-
ures) should be tuned more towards individual needs. This
means that, in the “functional foods” domain, uniform
approaches will probably not be maximally effective, thus
emphasising the need for greater knowledge on individual
consumer’s responses and the (deviations in) metabolism
that underlie the development of chronic anomalies. This
may not be a nice message for food producers, because
markets may fragment, but so be it; once more insight into
the underlying mechanisms has been obtained, a better
perspective on the chances of product development will be
obtained.
With respect to the impact of immunomodulatory foods
and food components on allergic reactions, as described in
this manuscript, it is striking that in all of the described
cases, a skewing of cytokine profiles from Th2 dominance
towards a more rebalanced state (read: an enhanced Th1
response) was observed. Secondly, in all cases the active
products or ingredients were microorganisms or products
derived from them. This leads to the hypothesis that, if
indeed an overly hygienic living environment and lifestyle
is the basis for the increase in allergic reactions, this
situation can perhaps be (partly) restored by exposure to
specific microbial constituents, likely activating innate
immunity and subsequently skewing adaptive immunity
towards a strengthened cell-mediated response: a little bit of
dirt does not seem to be bad!
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